Evidence map›Paper›PMID 25589550›Full record

ArticleClinical and vaccine immunology : CVI2015

Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units.

In Ho Park, K Aaron Geno, Jigui Yu, Melissa B Oliver, Kyung-Hyo Kim, Moon H Nahm

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Synthetic Analogs ofRussian journal of bioorganic chemistry · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

In Ho ParkCenter for Vaccine Evaluation and Study, Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Republic of Korea.
K Aaron GenoDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jigui YuDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Melissa B OliverDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kyung-Hyo KimCenter for Vaccine Evaluation and Study, Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Republic of Korea Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Republic of Korea kaykim@ewha.ac.kr nahm@uab.edu.
Moon H NahmDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA kaykim@ewha.ac.kr nahm@uab.edu.
University of Alabama at Birmingham · USEwha Womans University · KR

Funding

Pneumococcal capsule and host innate immunityR56AI031473 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NAHM, MOON H. · 2012 to 2012
$366k
NIAID NIH HHS R56 AI031473NIAID NIH HHS R56-AI-031473
6 · The paper itself

Abstract

Streptococcus pneumoniae clinical isolates were recently described that produced capsular polysaccharide with properties of both serotypes 6A and 6B. Their hybrid serological property correlated with mutations affecting the glycosyltransferase WciP, which links rhamnose to ribitol by an α(1-3) linkage for serotypes 6A and 6C and an α(1-4) linkage for serotypes 6B and 6D. The isolates had mutations in the triad residues of WciP that have been correlated with enzyme specificity. The canonical triad residues of WciP are Ala192-Ser195-Arg254 for serotypes 6A and 6C and Ser192-Asn195-Gly254 for serotypes 6B and 6D. To prove that the mutations in the triad residues are responsible for the hybrid serotype, we introduced the previously described Ala192-Cys195-Arg254 triad into a 6A strain and found that the change made WciP bispecific, resulting in 6A and 6B repeat unit expression, although 6B repeat unit production was favored over production of 6A repeat units. Likewise, this triad permitted a 6C strain to express 6C and 6D repeat units. With reported bispecificity in WciN, which adds either glucose or galactose as the second sugar in the serogroup 6 repeat unit, the possibility exists for a strain to simultaneously produce all four serogroup 6 repeat units; however, when genes encoding both bispecific enzymes were introduced into a 6A strain, only 6A, 6B, and 6D repeat units were detected serologically. Nonetheless, this may be the first example of a bacterial polysaccharide with three different repeat units. This strategy of expressing multiple repeat units in a single polymer is a novel approach to broadening vaccine coverage by eliminating the need for multiple polysaccharide sources to cover multiple serogroup members.

Indexed as

SerogroupBacterial CapsulesGlycosyltransferasesHybridomasMultilocus Sequence TypingMutagenesis, Site-DirectedPolysaccharides, BacterialSequence Analysis, DNASerotypingStreptococcus pneumoniaeGlycosyltransferasesPolysaccharides, Bacterial

Identifiers

PMID25589550
PMCPMC4340893
OpenAlexW2138181963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.